New 'Go-Slow' drug combo aims to help frailest myeloma patients

NCT ID NCT06517017

Recruiting now Disease control Sponsor: University of Utah Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a gradual, three-drug combination (isatuximab, dexamethasone, and lenalidomide) in 40 ultra-frail patients newly diagnosed with multiple myeloma. The goal is to see if starting treatment slowly improves how well patients tolerate therapy and their quality of life, since these patients are often too fragile for standard regimens.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: isatuximab, dexamethasone, and lenalidomide
What this could lead to: If successful, this could offer a more tolerable treatment option for ultra-frail multiple myeloma patients, potentially improving their quality of life and ability to stay on therapy.
What could go wrong: This is a small, early-phase trial with only 40 participants, so results may not apply to all patients. The go-slow approach might not control the cancer as effectively as standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell leukemia plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA PLASMA CELL LEUKEMIA

Contacts and locations

Locations

Huntsman Cancer Institute at the University of Utah
RECRUITING

Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.